Aandeel Celyad BRU:CYAD.BL, BE0974260896

quote:

MaGu schreef op 20 december 2021 10:26:

Niet heel verbazend dat het weer rood is toch?

quote:

MaGu schreef op 20 december 2021 10:58:

Ik moet van Egel wat positiever zijn over Celyad. Welnu: positive is dat wij niet bang hoeven te zijn dat het in de middag weer rood is!

quote:

TD_01 schreef op 20 december 2021 12:24:

2021 is een jaar om op vele vlakken snel te vergeten!!! Vele biotech bedrijven hebben prijs moeten geven afgelopen jaar, ook Celyad! Laat ons hopen dat 2022 beter wordt!! Ik geloof nog steeds dat er groeimarge inzit.

quote:

Garre schreef op 20 december 2021 13:24:

Tja, wat moet er in vredesnaam gebeuren...op naar 2022

quote:

groene appel schreef op 20 december 2021 15:29:

Celyad Oncology (NASDAQ:CYAD) Upgraded to “Buy” at Zacks Investment Research
December 19, 2021 ETF Daily News Team
Celyad Oncology SA logoZacks Investment Research upgraded shares of Celyad Oncology (NASDAQ:CYAD) from a hold rating to a buy rating in a report published on Wednesday, Zacks.com reports. The firm currently has $4.75 price target on the stock.

According to Zacks, “Celyad SA is a biopharmaceutical company. The Company develops and commercializes cell based regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. Celyad SA is based in Mont-Saint-Guibert, Belgium. “

Other analysts also recently issued research reports about the company. Jonestrading reiterated a hold rating on shares of Celyad Oncology in a research note on Friday, August 20th. HC Wainwright decreased their price target on Celyad Oncology from $15.00 to $13.00 and set a buy rating for the company in a research note on Friday, December 10th.

CYAD opened at $4.17 on Wednesday. The stock has a 50-day moving average of $4.28 and a 200-day moving average of $4.50. Celyad Oncology has a 52-week low of $3.53 and a 52-week high of $9.26. The company has a current ratio of 0.97, a quick ratio of 1.42 and a debt-to-equity ratio of 0.10.

A hedge fund recently bought a new stake in Celyad Oncology stock. Endurant Capital Management LP bought a new stake in shares of Celyad Oncology SA (NASDAQ:CYAD) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 160,691 shares of the company’s stock, valued at approximately $845,000. Endurant Capital Management LP owned 1.04% of Celyad Oncology as of its most recent SEC filing. 1.83% of the stock is currently owned by institutional investors.

About Celyad Oncology

Celyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through the following segments: Cardiology and Immuno-Oncology. The Cardiology segment includes the company’s Cardiopoiesis, Corquest, and C-Cathez platforms.

quote:

Hopende schreef op 20 december 2021 15:41:

we zijn voor de zoveelste keer de slechtste van de bel 20 Small dikke proficiat aan het bestuur van Celyad , Zalige kerst en een gelukkig nieuwjaar zal een lekker fles champagne zijn op onze kosten

quote:

StiMO schreef op 20 december 2021 15:59:

[...]

Had je dan niet verkocht ?

quote:

Hopende schreef op 20 december 2021 16:00:

[...]
1/3 2 weken gelden
en vorige week nog een 500 stuks
nog 3000 te gaan jammer genoeg

quote:

Galajurk schreef op 21 december 2021 00:32:

[...]

De koers van een aandeel wordt door veel factoren bepaald ,
O.a door de aandeelhouders , vraag en aanbod.
Dus als je aandelen verkoopt heeft dat een negatieve invloed op de koers…